Learn more

BAVARIAN NORDIC AS

Overview
  • Total Patents
    697
  • GoodIP Patent Rank
    8,336
  • Filing trend
    ⇩ 14.0%
About

BAVARIAN NORDIC AS has a total of 697 patent applications. It decreased the IP activity by 14.0%. Its first patent ever was published in 1996. It filed its patents most often in United States, EPO (European Patent Office) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are MEDIPOST CO LTD, BIOVEX LTD and NAT CENTER OF NEUROLOGY & PSYCHIATRY.

Patent filings per year

Chart showing BAVARIAN NORDIC ASs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Howley Paul 151
#2 Chaplin Paul 126
#3 Steigerwald Robin 110
#4 Leyrer Sonja 103
#5 Hochrein Hubertus 65
#6 Heller Karl 57
#7 Felder Eva 48
#8 Volkmann Ariane 46
#9 Suter Mark 44
#10 Dirmeier Ulrike 40

Latest patents

Publication Filing date Title
WO2020104531A1 Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
AU2019354101A1 Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
AU2019336940A1 Storage improved poxvirus compositions
AU2018389786A1 Methods and compositions for inducing an immune response against hepatitis B virus (HBV)
AU2018283811A1 Poxvirus vectors encoding HIV antigens, and methods of use thereof
CN110198733A For enhancing the composition and method of the stability of poxvirus transgenic
US2017137820A1 Agonists and antagonists of toll-like receptor (tlr) 13
WO2017129765A1 Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
US2017081642A1 Recombinant poxvirus vector comprising tetanus toxin fragment c
SG10202000447YA Promoters for enhancing expression in poxviruses
BR112018002172A2 promoters to enhance poxvirus expression
CN107709554A Restructuring is through modifying vaccinia virus ankara (MVA) foot and mouth disease virus (FMDV) vaccine
AU2015323736A1 Methods and compositions for intra-nasal immunization with recombinant MVA encoding flagellin
CA2960096A1 Methods and compositions for enhancing immune responses
CA2960092A1 Vaccine combination including vectors comprising nucleic acid encoding antigens from filovirus subtypes
CN106999565A Vaccinia virus ankara (MVA) filamentous virus vaccine of recombinant modified
AU2015203893A1 Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines
EP3142689A1 Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
US2017106065A1 Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3
EP3116541A1 Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus